A platinum(iv) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis

Guo Yan; Zhang Shuren; Yuan Hao; Song Dongfan; Jin Suxing; Guo Zijian; Wang Xiaoyong

首页> 外文期刊>Dalton transactions: An international journal of inorganic chemistry >A platinum(iv) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis

【24h】

A platinum(iv) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis

机译：通过破坏脉管系统和抑制转移来击败乳腺癌的铂（IV）前药

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

A Pt-IV prodrug (PDMA) exhibits great potential for the therapy of metastatic triple-negative breast cancer (TNBC) through a synergistic action of antiangiogensis and antimetastasis.

机译：PT-IV前药（PDMA）通过抗脑高血管和抗体抗抗体的协同作用表现出转移性三重阴性乳腺癌（TNBC）的巨大潜力。

著录项

来源
《Dalton transactions: An international journal of inorganic chemistry》 |2019年第11期|共5页
作者
Guo Yan; Zhang Shuren; Yuan Hao; Song Dongfan; Jin Suxing; Guo Zijian; Wang Xiaoyong;
展开▼
作者单位

Nanjing Univ Sch Chem &

Chem Engn State Key Lab Coordinat Chem Nanjing 210023 Jiangsu Peoples R China;

Nanjing Univ Sch Chem &

Chem Engn State Key Lab Coordinat Chem Nanjing 210023 Jiangsu Peoples R China;

Nanjing Univ Sch Chem &

Chem Engn State Key Lab Coordinat Chem Nanjing 210023 Jiangsu Peoples R China;

Nanjing Univ Sch Chem &

Chem Engn State Key Lab Coordinat Chem Nanjing 210023 Jiangsu Peoples R China;

Nanjing Univ Sch Life Sci State Key Lab Pharmaceut Biotechnol Nanjing 210023 Jiangsu Peoples R China;

Nanjing Univ Sch Chem &

Chem Engn State Key Lab Coordinat Chem Nanjing 210023 Jiangsu Peoples R China;

Nanjing Univ Sch Life Sci State Key Lab Pharmaceut Biotechnol Nanjing 210023 Jiangsu Peoples R China;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类化学;无机化学;
关键词

相似文献

外文文献
中文文献
专利

1. A platinum(iv) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis [J] . Guo Yan, Zhang Shuren, Yuan Hao, Dalton transactions: An international journal of inorganic chemistry . 2019,第11期

机译：通过破坏脉管系统和抑制转移来击败乳腺癌的铂（IV）前药
2. The novel platinum(IV) prodrug with self-assembly property and structure transformable character against triple-negative breast cancer [J] . Biomaterials . 2020,第期

机译：具有自组装性能的新型铂（IV）前药和结构可变形特征，对抗三重阴性乳腺癌
3. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo [J] . Ma Zhong-Ying, Wang Dong-Bo, Song Xue-Qing, European Journal of Medicinal Chemistry: Chimie Therapeutique . 2018,第期

机译：氯蛋白缀合的铂（IV）前药在体外和体内治疗三阴性乳腺癌
4. The synergistic effects of radiofrequency ablation (RFA) with glycated chitosan for inhibiting the metastasis of breast cancer [C] . Hsin-Yu Chiu, Jyh-Der Leu, Wei R. Chen, Biophotonics and immune responses XI . 2016

机译：射频消融（RFA）与糖基化壳聚糖协同抑制乳腺癌转移的作用
5. Dipeptidyl peptidase IV (DPP IV) mediates lung metastasis of rat breast cancer cells. [D] . Cheng, Hung-Chi. 2000

机译：二肽基肽酶IV（DPP IV）介导大鼠乳腺癌细胞的肺转移。
6. In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines [O] . Lukas Klameth, Barbara Rath, Gerhard Hamilton 2017

机译：口服铂（IV）前药氧铂和HSP90抑制剂Ganetespib对一组胃癌细胞系的体外细胞毒活性
7. Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer [O] . -1

机译：含胸苷合酶抑制剂和代谢改性剂的多透铂（IV）前药，对抗三阴性乳腺癌
8. Mouse Model for in Vivo Detection and Disruption of TGF-Beta Signaling in Breast Cancer Metastasis [R] . Korpal, M. 2009

机译：用于体内检测和破坏乳腺癌转移中TGF-β信号的小鼠模型

A platinum(iv) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis

摘要

著录项

相似文献

相关主题

期刊订阅